Breaking News

Financial Report: Lilly

April 24, 2014

Cymbalta and Evista patent expirations impact results

Lilly

1Q Revenues: $4.7 billion (-16%)

1Q Earnings: $749.9 million (-52%)

Comments: Results were impacted by U.S. patent expirations for Cymbalta (-64% to $478.2 million) and Evista (-38% to $150.1 million). Humalog sales were up 3% to $632.7 million. Alimta sales were up 2% to $632.0 million. Cialis sales were $532.4 million, up 3%. R&D expenses were down 18% to $1.1 billion. In the quarter, the company gained approval for Cyramza for advanced or metastatic gastric cancer, and entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision